Highlights
The global CAR-T Therapy market was valued at US$ million in 2022 and is anticipated to reach US$ million by 2029, witnessing a CAGR of % during the forecast period 2023-2029. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
North American market for CAR-T Therapy is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
Asia-Pacific market for CAR-T Therapy is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The global market for CAR-T Therapy in Acute Lymphocytic Leukemia is estimated to increase from $ million in 2023 to $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The key global companies of CAR-T Therapy include Novartis AG, Kite Pharma, Pfizer, Juno Therapeutics, Celgene Corporation, CARsgen Therapeutics, Sorrento Therapeutics, Legend Biotech and Atara Biotherapeutics, etc. In 2022, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for CAR-T Therapy, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding CAR-T Therapy.
The CAR-T Therapy market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global CAR-T Therapy market comprehensively. Regional market sizes, concerning products by type, by application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the CAR-T Therapy companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by type, by application, and by regions.
By Company
Novartis AG
Kite Pharma
Pfizer
Juno Therapeutics
Celgene Corporation
CARsgen Therapeutics
Sorrento Therapeutics
Legend Biotech
Atara Biotherapeutics
Aurora Biopharma
Autolus Therapeutics PLC
Bluebird
Carina Biotech
Segment by Type
CD19
CD22
Other
Segment by Application
Acute Lymphocytic Leukemia
Diffuse Large B Cell Lymphoma
Follicular Lymphoma
Chronic Lymphocytic Leukemia
Multiple Myeloma
Other
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of CAR-T Therapy companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global CAR-T Therapy Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 CD19
1.2.3 CD22
1.2.4 Other
1.3 Market by Application
1.3.1 Global CAR-T Therapy Market Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Acute Lymphocytic Leukemia
1.3.3 Diffuse Large B Cell Lymphoma
1.3.4 Follicular Lymphoma
1.3.5 Chronic Lymphocytic Leukemia
1.3.6 Multiple Myeloma
1.3.7 Other
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global CAR-T Therapy Market Perspective (2018-2029)
2.2 CAR-T Therapy Growth Trends by Region
2.2.1 Global CAR-T Therapy Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 CAR-T Therapy Historic Market Size by Region (2018-2023)
2.2.3 CAR-T Therapy Forecasted Market Size by Region (2024-2029)
2.3 CAR-T Therapy Market Dynamics
2.3.1 CAR-T Therapy Industry Trends
2.3.2 CAR-T Therapy Market Drivers
2.3.3 CAR-T Therapy Market Challenges
2.3.4 CAR-T Therapy Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top CAR-T Therapy Players by Revenue
3.1.1 Global Top CAR-T Therapy Players by Revenue (2018-2023)
3.1.2 Global CAR-T Therapy Revenue Market Share by Players (2018-2023)
3.2 Global CAR-T Therapy Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by CAR-T Therapy Revenue
3.4 Global CAR-T Therapy Market Concentration Ratio
3.4.1 Global CAR-T Therapy Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by CAR-T Therapy Revenue in 2022
3.5 CAR-T Therapy Key Players Head office and Area Served
3.6 Key Players CAR-T Therapy Product Solution and Service
3.7 Date of Enter into CAR-T Therapy Market
3.8 Mergers & Acquisitions, Expansion Plans
4 CAR-T Therapy Breakdown Data by Type
4.1 Global CAR-T Therapy Historic Market Size by Type (2018-2023)
4.2 Global CAR-T Therapy Forecasted Market Size by Type (2024-2029)
5 CAR-T Therapy Breakdown Data by Application
5.1 Global CAR-T Therapy Historic Market Size by Application (2018-2023)
5.2 Global CAR-T Therapy Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America CAR-T Therapy Market Size (2018-2029)
6.2 North America CAR-T Therapy Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America CAR-T Therapy Market Size by Country (2018-2023)
6.4 North America CAR-T Therapy Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe CAR-T Therapy Market Size (2018-2029)
7.2 Europe CAR-T Therapy Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe CAR-T Therapy Market Size by Country (2018-2023)
7.4 Europe CAR-T Therapy Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific CAR-T Therapy Market Size (2018-2029)
8.2 Asia-Pacific CAR-T Therapy Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific CAR-T Therapy Market Size by Region (2018-2023)
8.4 Asia-Pacific CAR-T Therapy Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America CAR-T Therapy Market Size (2018-2029)
9.2 Latin America CAR-T Therapy Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America CAR-T Therapy Market Size by Country (2018-2023)
9.4 Latin America CAR-T Therapy Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa CAR-T Therapy Market Size (2018-2029)
10.2 Middle East & Africa CAR-T Therapy Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa CAR-T Therapy Market Size by Country (2018-2023)
10.4 Middle East & Africa CAR-T Therapy Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Novartis AG
11.1.1 Novartis AG Company Detail
11.1.2 Novartis AG Business Overview
11.1.3 Novartis AG CAR-T Therapy Introduction
11.1.4 Novartis AG Revenue in CAR-T Therapy Business (2018-2023)
11.1.5 Novartis AG Recent Development
11.2 Kite Pharma
11.2.1 Kite Pharma Company Detail
11.2.2 Kite Pharma Business Overview
11.2.3 Kite Pharma CAR-T Therapy Introduction
11.2.4 Kite Pharma Revenue in CAR-T Therapy Business (2018-2023)
11.2.5 Kite Pharma Recent Development
11.3 Pfizer
11.3.1 Pfizer Company Detail
11.3.2 Pfizer Business Overview
11.3.3 Pfizer CAR-T Therapy Introduction
11.3.4 Pfizer Revenue in CAR-T Therapy Business (2018-2023)
11.3.5 Pfizer Recent Development
11.4 Juno Therapeutics
11.4.1 Juno Therapeutics Company Detail
11.4.2 Juno Therapeutics Business Overview
11.4.3 Juno Therapeutics CAR-T Therapy Introduction
11.4.4 Juno Therapeutics Revenue in CAR-T Therapy Business (2018-2023)
11.4.5 Juno Therapeutics Recent Development
11.5 Celgene Corporation
11.5.1 Celgene Corporation Company Detail
11.5.2 Celgene Corporation Business Overview
11.5.3 Celgene Corporation CAR-T Therapy Introduction
11.5.4 Celgene Corporation Revenue in CAR-T Therapy Business (2018-2023)
11.5.5 Celgene Corporation Recent Development
11.6 CARsgen Therapeutics
11.6.1 CARsgen Therapeutics Company Detail
11.6.2 CARsgen Therapeutics Business Overview
11.6.3 CARsgen Therapeutics CAR-T Therapy Introduction
11.6.4 CARsgen Therapeutics Revenue in CAR-T Therapy Business (2018-2023)
11.6.5 CARsgen Therapeutics Recent Development
11.7 Sorrento Therapeutics
11.7.1 Sorrento Therapeutics Company Detail
11.7.2 Sorrento Therapeutics Business Overview
11.7.3 Sorrento Therapeutics CAR-T Therapy Introduction
11.7.4 Sorrento Therapeutics Revenue in CAR-T Therapy Business (2018-2023)
11.7.5 Sorrento Therapeutics Recent Development
11.8 Legend Biotech
11.8.1 Legend Biotech Company Detail
11.8.2 Legend Biotech Business Overview
11.8.3 Legend Biotech CAR-T Therapy Introduction
11.8.4 Legend Biotech Revenue in CAR-T Therapy Business (2018-2023)
11.8.5 Legend Biotech Recent Development
11.9 Atara Biotherapeutics
11.9.1 Atara Biotherapeutics Company Detail
11.9.2 Atara Biotherapeutics Business Overview
11.9.3 Atara Biotherapeutics CAR-T Therapy Introduction
11.9.4 Atara Biotherapeutics Revenue in CAR-T Therapy Business (2018-2023)
11.9.5 Atara Biotherapeutics Recent Development
11.10 Aurora Biopharma
11.10.1 Aurora Biopharma Company Detail
11.10.2 Aurora Biopharma Business Overview
11.10.3 Aurora Biopharma CAR-T Therapy Introduction
11.10.4 Aurora Biopharma Revenue in CAR-T Therapy Business (2018-2023)
11.10.5 Aurora Biopharma Recent Development
11.11 Autolus Therapeutics PLC
11.11.1 Autolus Therapeutics PLC Company Detail
11.11.2 Autolus Therapeutics PLC Business Overview
11.11.3 Autolus Therapeutics PLC CAR-T Therapy Introduction
11.11.4 Autolus Therapeutics PLC Revenue in CAR-T Therapy Business (2018-2023)
11.11.5 Autolus Therapeutics PLC Recent Development
11.12 Bluebird
11.12.1 Bluebird Company Detail
11.12.2 Bluebird Business Overview
11.12.3 Bluebird CAR-T Therapy Introduction
11.12.4 Bluebird Revenue in CAR-T Therapy Business (2018-2023)
11.12.5 Bluebird Recent Development
11.13 Carina Biotech
11.13.1 Carina Biotech Company Detail
11.13.2 Carina Biotech Business Overview
11.13.3 Carina Biotech CAR-T Therapy Introduction
11.13.4 Carina Biotech Revenue in CAR-T Therapy Business (2018-2023)
11.13.5 Carina Biotech Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Novartis AG
Kite Pharma
Pfizer
Juno Therapeutics
Celgene Corporation
CARsgen Therapeutics
Sorrento Therapeutics
Legend Biotech
Atara Biotherapeutics
Aurora Biopharma
Autolus Therapeutics PLC
Bluebird
Carina Biotech
*If Applicable.